Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 697-707

  Fujimoto, Koichi ^a   Takemoto, Koji ^a   Hatano, Kazuo ^a   Nakai, Toru ^a   Terashit, Shigeyuki ^a,b   Matsumoto, Masahiro ^b   Eriguchi, Yoshiro ^a   Eguchi, Ken ^a   Shimizudani, Takeshi ^a   Sato, Kimihiko ^a   Kanazawa, Katsunori ^a   Sunagawa, Makoto ^a   Ueda, Yutaka ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYLASE; CARBAPENEM DERIVATIVE; CEFDITOREN; CLARITHROMYCIN; FROPENEM; LEVOFLOXACIN; MEROPENEM; SM 295291; SM 369926; TEBIPENEM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; COMMUNICABLE DISEASE; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG STABILITY; ENTEROCOCCUS FAECALIS; EXPERIMENTAL DOG; HAEMOPHILUS INFLUENZAE; HAPLORHINI; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CARBAPENEMS; COMMUNITY-ACQUIRED INFECTIONS; DIPEPTIDASES; DOGS; DRUG STABILITY; GPI-LINKED PROTEINS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84872834562     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01051-12     Document Type: Article

References (30)

1. Saga T, Yamaguchi K. 2009. History of antimicrobial agents and resistant bacteria. Jpn. Med. Assoc. J. 52:103-108.
2. Pakyz AL, Oinonen M, Polk RE. 2009. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:1983-1986.
3. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, Endtz HP, van Den Braak N, Fernandes CJ, Fernandes L, Frimodt-Moller N, Rasmussen LS, Giamarellou H, Giamarellos-Bourboulis E, Jarlier V, Nguyen J, Nord CE, Struelens MJ, Nonhoff C, Turnidge J, Bell J, Zbinden R, Pfister S, Mixson L, Shungu DL. 2001. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob. Agents Chemother. 45:1860-1867.
4. Daigle DM, Xerri L. 2008. Susceptibility of Pseudomonas aeruginosa to imipenem is unaffected by exposure to PZ-601 (SMP-601), poster C1-1064. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC, 25 to 28 October 2008. American Society for Microbiology, Washington, DC.
5. Livermore DM, Mushtaq S, Warner M. 2005. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J. Antimicrob. Chemother. 55:306-311.
6. Lee RWW, Lindstrom ST. 2007. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 12:111-116.
7. Ramirez JA. 1995. Switch therapy in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 22:219-223.
8. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. 1995. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. 155: 1273-1276.
9. Sunagawa M, Ueda Y, Okada S, Watanabe S, Hashizuka T, Hori S, Sasaki A, Eriguchi Y, Kanazawa K. 2005. Orally active carbapenem antibiotics. I. Antibacterial and pharmacokinetic potential of 2-phenyl and 2- thienylcarbapenems. J. Antibiot. 58:787-803.
10. Mizen L, Burton G. 1998. The use of esters as prodrugs for oral delivery of beta-lactam antibiotics. Pharm. Biotechnol. 11:345-365.
11. Takemoto K, Hatano K, Eguchi K, Hirai Y, Kanazawa K, Sunagawa M, Ueda Y. 2011. A new parenteral and oral 2-aryl carbapenem (CB): I. In vitro activity against antibiotic-susceptible and-resistant causative pathogens of community-acquired infections (CAIs), poster F1-139. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September 2011. American Society for Microbiology, Washington, DC.
12. Fujimoto K, Hatano K, Nakai T, Terashita S, Eriguchi Y, Urasaki K, Shimizudani T, Sato K, Kanazawa K, Sunagawa M, Ueda Y. 2011. A new parenteral and oral 2-aryl carbapenem (CB): II. Therapeutic efficacy against PRSP and BLNAR infection models and pharmacokinetics (PKs) in laboratory animals, poster F1-140. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September 2011. American Society for Microbiology, Washington, DC.
13. Ueda Y, Kanazawa K, Eguchi K, Takemoto K, Eriguchi Y, Sunagawa M. 2005. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob. Agents Chemother. 49:4185-4196.
14. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed; approved standard M11-A5. National Committee for Clinical Laboratory Standards, Wayne, PA.
15. Fukasawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki T, Okuda T, Matsumura H, Sunagawa M. 1992. Stability of meropenem and effect of 1?-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother. 36:1577-1579.
16. Sunagawa M, Itoh M, Kubota K, Sasaki A, Ueda Y, Angehrn P, Bourson A, Goetschi E, Hebeisen P, Then RL. 2002. New anti-MRSA and anti-VRE carbapenems; synthesis and structure-activity relationships of 1betamethyl-2-(thiazol-2- ylthio) carbapenems. J. Antibiot. 55:722-757.
17. Sunagawa M, Matsumura H, Sumita Y, Nouda H. 1995. Structural features resulting in convulsive activity of carbapenem compounds: Effect of C-2 side chain. J. Antibiot. 48:408-416.
18. Sumita Y, Nouda H, Tada E, Kohzuuki T, Kato M, Okuda T, Fukasawa M. 1992. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. Chemotherapy 40(Suppl 1):123-131.
19. Nicolau DP. 2008. Carbapenems: A potent class of antibiotics. Expert Opin. Pharmacother. 9:23-37.
20. Torii M, Takiguchi Y, Izumi M, Fukushima T, Yokota M. 2002. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. Int. J. Pharm. 233:253-256.
21. Nakashima M, Uematsu T, Oguma T, Yoshida T, Mizojiri K, Matsuno S, Yamamoto S. 1992. Phase I clinical studies of S-1108: Safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. Antimicrob. Agents Chemother. 36:762-768.
22. Hirouchi Y, Naganuma H, Kawahara Y, Okada R, Kamiya A, Inui K, Hori R. 1994. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn. J. Pharmacol. 66:1-6.
23. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: A critical review. Int. J. Antimicrob. Agents 19:261-268.
24. Sevillano D, Aguilar L, Alou L, Gimenez Gonzalez M-JN, Torrico M, Cafini F, Fenoll A, Coronel P, Prieto J. 2008. High protein binding and cidal activity against penicillin-resistant S. pneumoniae: A cefditoren in vitro pharmacodynamic simulation. PLoS One 3:e2717. doi:10.1371 /journal.pone.0002717.
25. Kijima K, Morita J, Suzuki K, Aoki M, Kato K, Hayashi H, Shibasaki S, Kurosawa T. 2009. Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals. Jpn. J. Antibiot. 62:214-240.
26. Kimura Y, Nakano M, Nakashimizu H, Nakamoto S, Watanabe Y, Otubo S, Matubara T, Sato S, Nara H, Yoshida T. 1993. Pharmacokinetics of S-1108, a new oral cephalosporin, in experimental animals. Chemotherapy 41(Suppl 1):163-176.
27. Matsumoto T, Okamoto J, Saito K, Aizawa K, Komiya I. 1992. Pharmacokinetics of ME1207, a novel oral cephem antibiotic, in experimental animals. Chemotherapy 40(Suppl 2):120-130.
28. Mitropoulos IF, Rotschafer JC, Rodvold KA. 2007. Adverse events associated with the use of oral cephalosporins/cephems. Diagn. Microbiol. Infect. Dis. 57:67S-76S.
29. Sjövall J, Huitfeldt B, Magni L, Nord CE. 1986. Effect of beta-lactam prodrugs on human intestinal microflora. Scand. J. Infect. Dis. Suppl. 49:73-84.
30. Stoeckel K, Hayton WL, Edwards DJ. 1995. Clinical pharmacokinetics of oral cephalosporins. Antibiot. Chemother. 47:34-71.